STAT3 and adenocarcinoma: Specifically, this study showed that multiple cancer cells (e.g., lymphoma, adenocarcinoma, breast and prostate cancer) maintain activated STAT3 persistently via SIP-S1PR1 signaling, without IL6-GP130 signaling26.